Gabapentin Capsule
Product Images NDC 25000-105

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 25000-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marksans Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba100mg 1000s Bottle

This packaging label is for Gabapentin Capsules, USP 100 mg, containing 1000 capsules. The label indicates it is a prescription drug (Rx only) and instructs pharmacists to dispense the medication guide separately. It includes storage instructions and manufacturer details for Marksans Pharma Ltd. The label features a purple and white design with barcode and regulatory information.*

FDA Label Image

Gaba100mg-30s-bott (Gaba100mg 30s Bottle)

Packaging label for Gabapentin Capsules, USP 100 mg, oral capsule form. The label indicates a package of 30 capsules, marked Rx only, manufactured by Marksans Pharma Ltd. It includes storage instructions and details of the manufacturer and distributor. The label features purple, white, blue, black, and red colors with the Marksans logo at the bottom left.*

FDA Label Image

Gaba100mg-500s-bott (Gaba100mg 500s Bottle)

Label for Gabapentin Capsules, USP 100 mg, oral dosage form, prescription drug. The label indicates a package size of 500 capsules and includes storage instructions, barcode, and manufacturer information for Marksans Pharma Ltd. The label prominently features the product name, strength, and pharmacist dispensing instructions.*

FDA Label Image

Gaba300mg 1000s Bottle

Label for Gabapentin Capsules, USP 300 mg by Marksans Pharma Limited. The label indicates 1000 capsules per container and includes storage instructions, manufacturer details (Time-Cap Labs, Inc. and Marksans Pharma Ltd.), a barcode, and a pharmacist dispensing note. The design features a blue and white background with green text for "300 mg."*

FDA Label Image

Gaba300mg-30s-bott (Gaba300mg 30s Bottle)

Gabapentin Capsules, USP 300 mg oral capsules label by Marksans Pharma Limited. The label indicates a package containing 30 capsules. It includes storage instructions, manufacturer details including Marksans Pharma Ltd. in India, and a barcode. The label is predominantly blue and white with green text highlighting the 300 mg strength.*

FDA Label Image

Gaba300mg-500s-bott (Gaba300mg 500s Bottle)

Label for Gabapentin Capsules, USP 300 mg oral capsules, manufactured by Marksans Pharma Limited and labeled for Time-Cap Labs, Inc. The label indicates Rx only, package of 500 capsules, and storage instructions. It includes a barcode and space for lot and expiration dates.*

FDA Label Image

Gaba400mg 1000s Bottle

Label for Gabapentin Capsules, USP 400 mg by Marksans Pharma Limited. The label indicates a prescription drug with 1000 capsules per container. It includes storage instructions and manufacturer information for Time-Cap Labs, Inc. and Marksans Pharma Ltd. The label features dosage strength, drug name, and barcode.*

FDA Label Image

Gaba400mg-30s-bott (Gaba400mg 30s Bottle)

Label for Gabapentin Capsules USP 400 mg, containing 30 capsules. The label includes storage instructions, manufacturing details for Marksans Pharma Ltd., and a barcode. The label features the Marksans logo and specifies the product as Rx only.*

FDA Label Image

Gaba400mg-500s-bott (Gaba400mg 500s Bottle)

Label for Gabapentin Capsules, USP 400 mg by Marksans Pharma Limited. The label indicates prescription use (Rx only), contains 500 capsules, and provides storage instructions (20° to 25°C, excursions permitted 15° to 30°C). Manufacturer details include Time-Cap Labs, Inc. (USA) and Marksans Pharma Ltd. (India). A barcode and spaces for lot and expiration dates are also shown.*

FDA Label Image

Structure Of Gaba (Gabapentin Figure 01)

Chemical structure diagram of gabapentin, showing its molecular arrangement with a cyclohexane ring, an amine group (CH2NH2), and a carboxyl group (CH2CO2H). This represents the active ingredient gabapentin.*

FDA Label Image

Figure-2 (Gabapentin Figure 02)

A line graph showing mean pain scores over 8 weeks. Two groups are compared: Placebo (open circles) and Gabapentin 3600 mg/day (closed triangles). The timeline includes a 4-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease more in the Gabapentin group than in the Placebo group over time.*

FDA Label Image

Figure-3 (Gabapentin Figure 03)

A line graph depicting the mean pain score over baseline and seven weeks for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, showing pain score trends for each treatment group over time.*

FDA Label Image

Figure-4 (Gabapentin Figure 04)

A bar chart showing the proportion of responders (patients with ≥ 50% reduction in pain score) at endpoint in controlled postherpetic neuralgia (PHN) studies for gabapentin (GBP) at different dosages compared to placebo (PBO). Study 1 displays 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels (p < 0.01 and p < 0.001) are noted.*

FDA Label Image

Figure-5 (Gabapentin Figure 05)

A scatter plot comparing percentage difference against daily dose in mg for three studies labeled a, b, and c. The graph shows data points at approximately 600, 900, 1200, and 1800 mg daily doses, with percentage differences ranging from about 7% to 18%. Study a is represented by black squares, Study b by gray squares, and Study c by white squares.*

FDA Label Image

Gabapentin Figure 06

A formula illustrating creatinine clearance (CLCr) calculation, showing variables including age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients (0.85). The formula is presented as a calculation involving these parameters.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.